GlassScriptPhysician profile
Tharakaram Ravishankar
NPI 1083709794
$27,413.28
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17K · 2020: $5,369 · 2021: $4,702 · 2022: $683.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $23,857.20 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $813.04 | 2019-2022 | |
| Amgen INC. | $663.26 | 2019-2021 | |
| Abbvie INC. | $397.33 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $345.13 | 2019-2022 | |
| Lilly USA, LLC | $213.56 | 2019-2022 | |
| Mannkind Corporation | $185.43 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $184.24 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $182.00 | 2019-2021 | |
| Esperion Therapeutics, INC. | $168.03 | 2020-2022 | |
| Insulet Corporation | $135.12 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $100.54 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $63.80 | 2021-2022 | |
| Ibsa Pharma INC. | $24.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $22.77 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $20.45 | 2022 | |
| Amryt Pharma Holdings LTD | $19.35 | 2022 | |
| Corcept Therapeutics | $17.31 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tharakaram Ravishankar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.